The milestone payment of E2.5 million was triggered by enrolling the seventh patient in the multinational Fentanyl Taifun Phase III program in late December 2008.
Enrollment is ongoing in a number of European study centers and further sites will be initiated during this quarter in both Europe and India.
Janssen Pharmaceutica is the licensee for the product in Europe, Canada, Middle East and Africa.